Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447676 · ClinicalTrials.gov registry record · Early Phase 1
Effects of 4-AP on Functional SCI Recovery
A Early Phase 1 study, sponsored by Shirley Ryan AbilityLab.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT05447676: Completed Early Phase 1 study, sponsored by Shirley Ryan AbilityLab.
NCT05447676 is a Early Phase 1 study that has completed, run by Shirley Ryan AbilityLab. The registered enrollment target is 26 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05447676, a Early Phase 1 study, has completed, sponsored by Shirley Ryan AbilityLab.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Primary Outcome
Electrical stimulation will be performed placing the cathode on the upper thoracic between the spinal processes between T3 and T4 vertebrae and the anode at \~10 cm above
Interventions
- BEHAVIORAL Exercise training
- DRUG Dalfampridine
- OTHER STDP stimulation
- OTHER Placebo drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2025-06-30 |
| Phase | Early Phase 1 |
What the finished NCT05447676 record still lists
NCT05447676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 4 interventions - of which Exercise training is the first listed.
NCT05447676 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05447676 about?
NCT05447676 is a clinical study titled "Effects of 4-AP on Functional SCI Recovery". The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP ...
What is the current status of trial NCT05447676?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2022-06-30. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05447676?
The interventions under investigation include: Exercise training (BEHAVIORAL), Dalfampridine (DRUG), STDP stimulation (OTHER), Placebo drug (OTHER).
Who is sponsoring clinical trial NCT05447676?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05447676's enrollment target sits among peer trials
26 977th of 2000 higher than 1,002 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI